The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Myelodysplasia-related mutation dynamics and outcomes in patients with newly diagnosed AML
Naszrin Arani, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides insight into the findings of a retrospective analysis of myelodysplasia-related mutation dynamics and outcomes among patients with newly diagnosed acute myeloid leukemia (AML) treated with lower-intensity therapy. Dr Arani highlights that patients who cleared their myelodysplasia-related mutations at best response had superior overall survival (OS) and relapse-free survival (RFS), and suggests that these observations could help guide treatment decisions if validated prospectively. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
